News

Veterans Exploring Treatment Solutions (VETS) Applauds White House Executive Order Advancing Ibogaine Research, Urges Accelerated Scientific Investment

Press Release: Ohio State Study Follows VETS Grant Recipients for Nine Months After Psychedelic Treatment

Press Release: VETS Grant Recipients Show Sustained Improvement at One Year in Stanford Medicine Magnesium-Ibogaine Follow-Up

Veterans Experience Major PTSD and Depression Relief From Psychedelic Drug Ibogaine

This news report examines Stanford Medicine’s one-year follow-up study of Special Operations veterans who received ibogaine treatment, supported in part by VETS, and how the findings add to the growing body of research and federal attention on psychedelic-assisted therapy for veterans.

One year after taking ibogaine, veterans find continued relief from PTSD

A new Stanford Medicine study published in Translational Psychiatry follows Special Operations veterans for one year after ibogaine treatment, funded by VETS at a vetted, third-party facility, offering the most extensive look to date at the long-term potential of this therapy for PTSD, depression, and anxiety.

Without Connection, There is Suffering: Chris “CT” Thompson on Healing, Community and the People Who Stay

Green Beret veteran and former VETS grant recipient Chris "CT" Thompson, now VETS' Director of Community Engagement, shares why connection, community, and integration support matter long after treatment.

VETS Celebrates Governor Newsom’s Signing of AB 113, Delivering California’s First-Ever State Investment in Veteran Psychedelic-Assisted Therapy Research

$4.7 million appropriation to the Office of Precision Medicine marks the third consecutive year veteran advocates have advanced psychedelic research legislation in California, one of the largest veteran-specific state investments in U.S. history

Healing Does Not Happen Alone: Dr. Lori Camper on Integration, Family, and Community after Treatment

VETS Programs Director Dr. Lori Camper shares why healing extends beyond treatment, highlighting the importance of integration, family support, community, and intentional daily changes as veterans continue their healing journey at home.

MDMA and the FDA, Take Two

VETS Policy Director Logan Davidson weighs in on Resilient Pharmaceuticals' renewed FDA application for MDMA-assisted therapy, calling it a meaningful step toward the rigorous, science-backed treatment options veterans with treatment-resistant PTSD deserve.

Legislative Progress Q2 2026: Building the Infrastructure for What Comes Next

A look at Q2 2026's legislative progress on veteran access to psychedelic-assisted therapy, from new state research funding and trigger laws to a federal Executive Order and VETS-led advocacy days at statehouses in North Carolina and Massachusetts.